Gyre Therapeutics (GYRE) EPS (Weighted Average and Diluted): 2009-2025
Historic EPS (Weighted Average and Diluted) for Gyre Therapeutics (GYRE) over the last 9 years, with Sep 2025 value amounting to $0.03.
- Gyre Therapeutics' EPS (Weighted Average and Diluted) rose 200.00% to $0.03 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.08, marking a year-over-year increase of 105.48%. This contributed to the annual value of $0.05 for FY2024, which is 103.55% up from last year.
- Latest data reveals that Gyre Therapeutics reported EPS (Weighted Average and Diluted) of $0.03 as of Q3 2025, which was up 200.00% from $0.01 recorded in Q3 2024.
- Gyre Therapeutics' EPS (Weighted Average and Diluted)'s 5-year high stood at $1.64 during Q2 2022, with a 5-year trough of -$1.51 in Q4 2023.
- Its 3-year average for EPS (Weighted Average and Diluted) is -$0.17, with a median of $0.03 in 2023.
- Examining YoY changes over the last 5 years, Gyre Therapeutics' EPS (Weighted Average and Diluted) showed a top increase of 310.26% in 2022 and a maximum decrease of 100.00% in 2022.
- Quarterly analysis of 5 years shows Gyre Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.64 in 2021, then tumbled by 100.00% to -$1.28 in 2022, then fell by 17.97% to -$1.51 in 2023, then slumped by 80.00% to $0.01 in 2024, then surged by 200.00% to $0.03 in 2025.
- Its EPS (Weighted Average and Diluted) stands at $0.03 for Q3 2025, versus $0.01 for Q3 2024 and $0.01 for Q2 2024.